- E-postper.lonning@uib.no
- Telefon+47 55 97 20 10
- BesøksadresseHaukeland universitetssykehus, Laboratoriebygget5009 Bergen
- PostadressePostboks 78045020 Bergen
Professor Per Eystein Lønning har arbeidet sammenhengende innenfor kreftbehandling og forskning fra 1982. Han har fra 1990 vært overlege ved Kreftavdelingen, Haukeland Sykehus, og fra 1992 Professor ved Universitetet i Bergen. Han leder Brystkreftgruppen ved Mohn kreftforskningslaboratorium. Gruppen, som i alt teller vel 20 medlemmer, arbeider hovedsakelig med brystkreft men og med andre kreftsykdommer, som tykktarmskreft og føflekkkreft. Gruppen består av forskere i Mohn Kreftforskningslaboratorium samt leger ved Kreftavdelingen, der flere i likhet med Lønning arbeider både med pasientbehandling og laboratorie-forskning. Lønning har arbeidet både med virkningsmekanismene for hormonell behandling samt cellegift ved brystkreft, og i tillegg arbeidet med kreftrisiko-faktorer. Hovedfeltet nå er mekanismer for resistens mot cellegift.
- (2010). Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 1790-1801.
- (2010). Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 294-299.
- (2010). Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 3356-3367.
- (2010). Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs. S19-S30.
- (2010). Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology. 288-293.
- (2010). DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Molecular Cancer. 13 sider.
- (2010). Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 386-395.
- (2010). Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 237-241.
- (2009). Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 31-41.
- (2009). Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
- (2009). A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research. 4165-4173.
- (2008). The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 5182-5194.
- (2008). Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 577-585.
- (2008). Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 6330-6335.
- (2008). GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Research. 5562-5571.
- (2008). Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. S11-S13.
- (2008). Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology. 196-202.
- (2008). Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist. 829-837.
- (2008). An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology. 90-95.
- (2007). Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica.
- (2007). Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 27-34.
- (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 559-570.
- (2007). Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research (NAR). 7267-7278.
- (2007). Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research (NAR). 7267-7278.
- (2007). Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. 908-910.
- (2007). Aromatase inhibitors-Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology. 55-61.
- (2007). Adjuvant endocrine treatment of early breast cancer. Hematology/Oncology Clinics of North America. 223-238.
- (2006). Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical and Experimental Immunology. 53-58.
- (2006). Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. Journal of Cell Science. 3284-3295.
- (2006). Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 2914-2918.
- (2006). Antitumor efficacy improved by local delivery of species-specific endostatin. Journal of Neurosurgery. 118-128.
- (2006). Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 1131-1140.
- (2005). Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 291-300.
- (2005). Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 26-33.
- (2005). Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 105-111.
- (2005). Aromatasehemmere i behandling av brystkreft. Tidsskrift for Den norske legeforening. 723-728.
- (2005). Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 23-31.
- (2005). Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 137-142.
- (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
- (2000). Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
- (2000). Pharmacology and clinical experience with exemestane. Experimental Opinion Investigation Drugs. 1897-1905.
- (2000). Molecular portraits of human breast tumours. Nature. 747-752.
- (2000). Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
- (2000). Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
- (2000). Exemestane in breast cancer: Current status and future directions. Clinical Breast Cancer. S28-S33.
- (2000). Endocrine therapy for treatment of breast cancer. Polish Oncology Journal of Nowotwory. 50-53.
- (2000). Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer. S81-S82.
- (2000). Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
- (2000). A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
- (1999). TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
- (1999). TP53 as a predictor of response to chemotherapy in breast cancer. Review. European School of Oncology Scientific Updates. 73-88.
- (1999). TP53 as a predictor of response to chemotherapy in breast cancer. European School of Oncology Scientific Updates. 73-88.
- (1999). Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
- (1999). Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
- (1999). Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer. 891-898.
- (1999). Plasma estrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. Endocrinology. 265-270.
- (1999). Influence of aromatase inhibitors on plasma total homocysteine levels in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
- (1999). Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
- (1999). Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
- (1999). Effect of treatment with megestrol acetate on the IGF-system: Time and dose dependency. European Journal of Cancer. 1070-1075.
- (1999). Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocrine-Related Cancer. 251-257.
- (1999). CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to SP-1. Cancer Research. 2825-2828.
- (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
- (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
- (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
- (1998). Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
- (1998). Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment. s53-s57.
- (1998). Microencapsulated octreotide pamoate in advanced cancer. British Journal of Cancer. 14-20.
- (1998). Kinetics of total plasma homocysteine during basal conditions. Clinical Chemistry. 1886-1891.
- (1998). Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy. Clinical Chemistry. 1987-1989.
- (1998). Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
- (1998). Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 159-163.
- (1998). Influence of treatment with aminoglutethimide on plasma and red-blood-cell gluthatione status in breast cancer patients. Cancer Chemotherapy and Pharmacology. 46-52.
- (1998). Influence of droloxifene on metastatic breast cancer as first line endocrine treatment. Acta Oncologica. 365-368.
- (1998). Influence of dexaminoglutethimide, optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patie. Journal of Clinical Endocrinology and Metabolism (JCEM). 2687-2693.
- (1998). In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breat cancer patients. Clinical Cancer Research. 2089-2093.
- (1998). Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
- (1998). Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
- (1998). Aromatase inhibitors and their future role in postmenopausal women with early breast cancer. British Journal of Cancer. 12-15.
- (1998). Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. Maturitas. 259-265.
- (1997). Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology. 255-260.
- (1997). Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology. 151-155.
- (1997). Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clinical Cancer Research. 1101-1108.
- (1997). Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
- (1997). Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
- (1997). Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
- (1997). Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
- (1997). Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
- (1997). Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
- (1997). Anastrozole - A new generation in aromatase inhibition: Clinical pharmacology. Oncology. 11-14.
- (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
- (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
- (1997). Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
- (1996). Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. European Journal of Cancer. 789-792.
- (1996). Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
- (1996). Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
- (1996). Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clinical Cancer Research. 1515-1521.
- (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
- (1996). Pharmacology of new aromatase inhibitors. Breast. 202-208.
- (1996). Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. International Journal of Cancer, Predictive Oncology. 335-339.
- (1996). Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 335-341.
- (1996). Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-I IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 167-171.
- (1996). Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer. 1286-1291.
- (1996). Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisatin and plasma oestrogen levels in post-menopausal women with breast cancer. British Journal of Cancer. 1286-1291.
- (1996). Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF)I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. Journal of Clinical Endocrinology and Metabolism (JCEM). 2216-2221.
- (1996). Aromatase inhibition for breast cancer treatment. Acta Oncologica. 38-43.
- (1995). Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
- (1995). Relations between sex hormones, sex hormone binding globulin insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clinical Endocrinology. 23-30.
- (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
- (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
- (1995). Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Research and Treatment. 287-297.
- (1995). Insulin-like growth factors in breast and prostatic cancer. Endocrine-Related Cancer. 153-169.
- (1995). Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
- (1995). Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
- (1995). Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 193-195.
- (1995). Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
- (1995). Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
- (1995). Alterations in plasma IGF-I caused by hormone manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer? Endocrine-Related Cancer. 127-130.
- (1994). Treatment of relapse of breast cancer after adjuvant systemic therapy - review and guidelines for future research. European Journal of Cancer. 106-111.
- (1994). Systemic therapy in breast cancer: Efficacy and cost utility. Pharm Econ. 198-212.
- (1994). Primærbehandling av lokalavansert brystkreft med bruk av neoadjuvant kjemoterapi. Tidsskrift for Den norske legeforening. 668-670.
- (1994). Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
- (1994). Combined treatment with 4-hydroxyandrostendione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. British Journal of Cancer. 1171-1175.
- (1993). Use of endocrine therapy to study the biology of breast cancer. Cancer Treatment Reviews. 65-77.
- (1993). Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxy-androstenedione. British Journal of Cancer. 393-398.
- (1993). Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
- (1993). Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
- (1993). Dose response evaluation - Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clinical Pharmacokinetics. 1-5.
- (1993). Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism And Disposition. 1119-1124.
- (1992). The influence of intramuscular 4-hydroxyandrostenedione on peripheral aramotisation in breast cancer patients. European Journal of Cancer. 1712-1716.
- (1992). The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer. 692-697.
- (1992). Prognostiske parametre ved lokalisert brystkreft. Prognostic parameters in early breast cancer. Tidsskrift for Den norske legeforening. 757-759.
- (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
- (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
- (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
- (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
- (1992). Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
- (1992). Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
- (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
- (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
- (1992). Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patient on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment. 57-62.
- (1992). Disposition of new endocrine drugs used in the treatment of advanced breast cancer. Clinical Pharmacokinetics. 327-358.
- (1992). Disposition of new endocrine drugs used in the treatment of advanced breast cancer. Clinical Pharmacokinetics. 327-358.
- (1992). Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clinical Pharmacokinetics. 327-358.
- (1992). Aromatase inhibitors in malignant diseases of aging. Drugs & Aging. 530-545.
- (1992). Aromatase activity, plasma oestradiol and their correlation with demographic indices in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 769-771.
- (1991). Wie wirkungsvoll ist das Mammographie-Screening? Deutsche Medizinische Wochenschrift. 108-112.
- (1991). Treatment of early breast cancer with conservation of the breast. Acta Oncologica. 779-792.
- (1991). Treatment of breast cancer with aromatase inhibitors. Medicamentos de actualidad. 117-132.
- (1991). The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer. 789-793.
- (1991). Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemotherapy and Pharmacology. 367-372.
- (1991). Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. Journal of enzyme inhibition (Print). 315-325.
- (1991). Leser-Zuschriften - Mammographie-Screening. Deutsche Medizinische Wochenschrift. 636-637.
- (1991). Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione ("pyridoglutethimide") in postmenopausal breast cancer patients. British Journal of Cancer. 887-894.
- (1991). Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. British Journal of Cancer. 641-645.
- (1991). Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. British Journal of Cancer. 641-645.
- (1991). Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. British Journal of Cancer. 641-645.
- (1991). Aromatase inhibitors - future prospects. Int Congr Symp Series. 55-59.
- (1990). Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-2. A differential effect of megestrol acetate a medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. Journal of Steroid Biochemistry. 105-109.
- (1990). Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-1. General findings. Journal of Steroid Biochemistry. 99-104.
- (1990). Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megastrol acetate in postmenopausal patients with advanced brea cancer. Cancer Chemotherapy and Pharmacology. 101-105.
- (1990). Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
- (2012). Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
- (2011). GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
- (2010). Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
- (2010). Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
- (1999). Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
- (1999). Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
- (1995). A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
- (1994). Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
- (1994). Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
- (2004). Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
- (2010). Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
- (2009). Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
- (2009). DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
- (2008). ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
- (2008). Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
- (2008). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
- (2007). Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
- (2007). Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
- (2007). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
- (2005). The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
- (2019). Constitutional mosaic epimutations - A hidden cause of cancer? Cell stress. 118-135.
- (2016). Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. Journal of Clinical Oncology. 1580-1583.
- (2015). Estradiol measurement in translational studies of breast cancer. Steroids. 26-31.
- (2014). The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy. 681-700.
- (2013). Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene. 5315-5330.
- (2013). Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-Related Cancer. R183-R201.
- (2012). P53 and its molecular basis to chemoresistance in breast cancer. Expert opinion on therapeutic targets. S23-S30.
- (2011). The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology. 503-514.
- (2011). Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. Clinical Cancer Research. 4948-4958.
- (2010). Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy. 1825-1836.
- (2010). Molecular basis for therapy resistance. Molecular Oncology. 284-300.
- (2009). Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? European Journal of Cancer. 527-535.
- (2009). Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
- (2009). Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncologica. 1092-1101.
- (2008). Indications and limitations of third-gene ration aromatase inhibitors. Expert Opinion on Investigational Drugs. 723-739.
- (2007). Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology. 1293-1306.
- (2006). Aromatase inhibitors as adjuvant treatment of breast cancer. Critical Reviews in Oncology/Hematology. 53-61.
- (2004). Aromatase inhibitors in breast cancer. Endocrine-Related Cancer. 179-189.